452 related articles for article (PubMed ID: 35924241)
1. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
2. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma.
Wang F; Liu H; Bai Y; Li H; Wang Z; Xu X
J Clin Lab Anal; 2021 Nov; 35(11):e24025. PubMed ID: 34569662
[TBL] [Abstract][Full Text] [Related]
3. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.
Yang C; Guo L; Du J; Zhang Q; Zhang L
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540686
[TBL] [Abstract][Full Text] [Related]
4. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma.
Huang K; Xie W; Wang S; Li Q; Wei X; Chen B; Hua Y; Li S; Peng B; Shen S
J Invest Surg; 2021 Sep; 34(9):1011-1020. PubMed ID: 32066292
[TBL] [Abstract][Full Text] [Related]
5. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Role of SPINK1 in Differentiating Hepatocellular Carcinoma From Nonmalignant Lesions.
Holah NS; El-Azab DS; Aiad HAE; Sweed DMM
Appl Immunohistochem Mol Morphol; 2017; 25(10):703-711. PubMed ID: 27028242
[TBL] [Abstract][Full Text] [Related]
7. Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis.
Yan RR; Zhu T; Wang Q; Yang K; Li J; Guan SH
Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491427
[TBL] [Abstract][Full Text] [Related]
8. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.
Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O
Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719
[TBL] [Abstract][Full Text] [Related]
10. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma.
Lu F; Shah PA; Rao A; Gifford-Hollingsworth C; Chen A; Trey G; Soryal M; Talat A; Aslam A; Nasir B; Choudhry S; Ishtiaq R; Sanoff H; Conteh LF; Noonan A; Hu KQ; Schmidt C; Fu M; Civan J; Xiao G; Lau DT; Lu X
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00271. PubMed ID: 33512798
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
12. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
[TBL] [Abstract][Full Text] [Related]
13. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases.
Zhu C; Han H; Li J; Xu L; Liu F; Wu K; Liu X
Biomed Res Int; 2019; 2019():9321494. PubMed ID: 31240230
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples.
Lu Y; Ren X; Zhou C; Chen H; Fan Y; Wang C
Comb Chem High Throughput Screen; 2022; 25(13):2165-2179. PubMed ID: 35232347
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
Cheung CCL; Seah YHJ; Fang J; Orpilla NHC; Lau MC; Lim CJ; Lim X; Lee JNLW; Lim JCT; Lim S; Cheng Q; Toh HC; Choo SP; Lee SY; Lee JJX; Liu J; Lim TKH; Tai D; Yeong J
Front Immunol; 2023; 14():1150985. PubMed ID: 37342338
[TBL] [Abstract][Full Text] [Related]
18. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
[TBL] [Abstract][Full Text] [Related]
19. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
20. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
Wan JL; Wang B; Wu ML; Li J; Gong RM; Song LN; Zhang HS; Zhu GQ; Chen SP; Cai JL; Xing XX; Wang YD; Yang Y; Cai CZ; Huang R; Liu H; Dai Z
Cancer Lett; 2022 Aug; 541():215750. PubMed ID: 35609735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
